Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3

Blood (2023) 142 (Supplement 1): 3357.

https://doi.org/10.1182/blood-2023-178009

Published: 2023

Journal Articles

Pooled Safety Analysis from Phase I-III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib

Pier Luigi Zinzani, Muhit Özcan, Marcelo Capra, Armando Santoro, Panayiotis Panayiotidis, Krimo Bouabdallah, Wojciech Jurczak, Charles Phelps, Florian JR Hiemeyer, Lidia Mongay Soler, Jose Garcia-Vargas, Barrett H. Childs, Georg Lenz, Matthew J. Matasar, Martin Dreyling

Blood (2022) 140 (Supplement 1): 6470–6473.

https://doi.org/10.1182/blood-2022-167368

Published: 2022

Journal Articles

Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Subgroup Analysis By Number of Prior Lines of Treatment

Marcelo Capra, Thomas Martin, Philippe Moreau, Gracia Martinez, Albert Oriol, Youngil Koh, Hang Quach, Kwee Yong, Andreea Rawlings, Christina Tekle, Sandrine Macé, Marie-Laure Risse, Ivan Spicka

Blood (2022) 140 (Supplement 1): 7138–7140.

https://doi.org/10.1182/blood-2022-162731

Published: 2022

Journal Articles

Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab

Matthew J. Matasar, Marcelo Capra, Muhit Özcan, Fangfang Lv, Wei Li, Eduardo Yañez, Katya Sapunarova, Tongyu Lin, Jie Jin, Wojciech Jurczak, Aryan Hamed, Ming-Chung Wang, Lidia Mongay Soler, Anjun Cao, Florian Hiemeyer, Barrett H Childs, Yuankai Shi, Pier Luigi Luigi Zinzani

Blood (2021) 138 (Supplement 1): 3538.

https://doi.org/10.1182/blood-2021-150873

Published: 2021

Journal Articles

Nanatinostat (Nstat) and Valganciclovir (VGCV) in Relapsed/Refractory (R/R) Epstein-Barr Virus-Positive (EBV + ) Lymphomas: Final Results from the Phase 1b/2 VT3996-201 Study

Bradley M. Haverkos, Onder Alpdogan, Robert Baiocchi, Jonathan E Brammer, Tatyana A. Feldman, Marcelo Capra, Elizabeth A Brem, Santosh M Nair, Phillip Scheinberg, Juliana Pereira, Leyla Shune, Erel Joffe, Afton Katkov, Robert McRae, Ivor Royston, Lisa Rojkjaer, Pierluigi Porcu

Blood (2021) 138 (Supplement 1): 623.

https://doi.org/10.1182/blood-2021-152603

Published: 2021

Journal Articles

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

Meletios Dimopoulos, Sara Bringhen, Pekka Anttila, Marcelo Capra, Michele Cavo, Craig Cole, Cristina Gasparetto, Vania Hungria, Matthew Jenner, Vladimir Vorobyev, Eduardo Yanez Ruiz, Jian Y. Yin, Rao Saleem, Maeva Hellet, Sandrine Macé, Bruno Paiva, Ravi Vij

Blood (2021) 137 (9): 1154–1165.

https://doi.org/10.1182/blood.2020008209

Published: 2021

Includes: Supplemental data

Journal Articles

Oral Nanatinostat (Nstat) and Valganciclovir (VGCV) in Patients with Recurrent Epstein-Barr Virus (EBV)-Positive Lymphomas: Initial Phase 2 Results

Pierluigi Porcu, MD, Bradley Haverkos, MD MPH, MS, Onder Alpdogan, MD, Robert Baiocchi, MD PhD, Jonathan E Brammer, MD, Tatyana A. Feldman, MD, Marcelo Capra, MD PhD, Elizabeth A Brem, MD, Phillip Scheinberg, MD, Juliana Pereira, MD PhD, Leyla Shune, MD, Afton Katkov, MSc, Robert McRae, Lisa Rojkjaer, MD, Ivor Royston, MD, Douglas V. Faller, MD PhD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-140843

Published: 2020

Journal Articles

Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis

Marcelo Capra, MD PhD, Thomas Martin, III, MD, Philippe Moreau, MD, Ross Baker, MBBS, FRACP, FRCPA, BSc, Ludek Pour, MD, Chang-Ki Min, MD PhD, Xavier Leleu, MD, Mohamad Mohty, MD PhD, Marta Reinoso Segura, Mehmet Turgut, MD, Richard Leblanc, MD FRCPC, Marie-Laure Risse, Laure Malinge, Sandrine Schwab, Meletios A Dimopoulos

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136415

Published: 2020

Journal Articles

Brazilian Real-World Multiple Myeloma (MM) Electronic Platform Register Project

Edvan De Queiroz Crusoe, MDPhD, Glaciano Ribeiro, MD, Karla Richter Zanella, MD, Leila Martins Perobelli, MD, Milton A. F. Aranha, MD, Marcelo Capra, MD PhD, Roberto José Pessoa Magalhães, MD, James Maciel, Rosane Bittencourt, MD, Emanuella Souza, Rafael Dezen Gaiolla, PhDMD, Walter Braga, MD, Fabiana Higashi, MD, Gracia Martinez, MD PhD, Abrahão Elias Hallack Neto, MD PhD, Danielle Leao Cordeiro De Farias, MDMSc,MBA, Virgilio Costa Farnese, MD, Nelson S Castro, MD, Renato Tavares, MD, Jacqueline Holanda De Souza, MD, Jandey Glória Bigonha, MD, Ederson Roberto Mattos, MD, Caroline Sola, MD, Joao Tadeu Souto Filho, MDPhD, LUiza da Silva, MD, Cleder Aparecido Da Silva Da Silva Araujo, MD, Jorge Vaz Pinto Neto, MD, Emanuel Silva, MD, Nelson Hamerschlak, MD PhD, Fabio Moore Nucci, MDPhD, Eduardo Flavio Oliveira Ribeiro, MD, Rafael Cunha, MD, Andre H Crepaldi, MD, Manuella Sampaio Almeida, MD, Gislaine B O Duarte, MD, Andre Magalhaes, MD, Dani Laks, MD PhD, Marcos Daniel, MD, Angelo Maiolino, MD, Vania T. M. Hungria, MD PhD

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-142072

Published: 2020

Journal Articles

Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refractory (R/R) Epstein-Barr Virus (EBV)-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results from a Phase 1b/2a Study

Blood (2019) 134 (Supplement_1): 465.

https://doi.org/10.1182/blood-2019-132004

Published: 2019

Journal Articles

Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Meletios A Dimopoulos, MD, Sara Bringhen, MD, Pekka Anttila, MD, Marcelo Capra, MD PhD, Michele Cavo, MD, Craig E. Cole, MD, Cristina J Gasparetto, MD, Vania T. M. Hungria, MD PhD, Matthew Jenner, Vladimir Vorobyev, MD PhD, Eduardo Yanez Ruiz, Jianyun Yin, Anthony Hamlett, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 155.

https://doi.org/10.1182/blood-2018-155

Published: 2018

Journal Articles

Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies

Blood (2018) 132 (Supplement 1): 3288.

https://doi.org/10.1182/blood-2018-99-112669

Published: 2018

Journal Articles

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor

Suzanne Lentzsch, Hang Quach, MBBS, MD, Asher A. Chanan-Khan, MD, Noemi Horvath, FRACP, Marcelo Capra, MD PhD, Roberto Ovilla, MD, Jae-Cheol Jo, MD, Ho-Jin Shin, MD, Piruntha Thiyagarajah, Himal Amin, Tineke Casneuf, PhD, Pieter Sonneveld, MDPhD, Jordan Schecter, Vania T M Hungria, MD PhD

Blood (2017) 130 (Supplement 1): 1852.

https://doi.org/10.1182/blood.V130.Suppl_1.1852.1852

Published: 2017

Journal Articles

Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor

Asher A. Chanan-Khan, MD, Suzanne Lentzsch, MD PhD, Hang Quach, MBBS (Hons), FRACP, FRCPA, MD, Noemi Horvath, MB, ChB, FRACP, FRCPA, Marcelo Capra, MD PhD, Roberto Ovilla, MD PhD, Jae-Cheol Jo, MD PhD, Ho-Jin Shin, MD PhD, Ming Qi, William Deraedt, Jordan Schecter, Himal Amin, Xiang Qin, Tineke Casneuf, Christopher Chiu, A. Kate Sasser, Pieter Sonneveld, MD PhD

Blood (2016) 128 (22): 3313.

https://doi.org/10.1182/blood.V128.22.3313.3313

Published: 2016

Journal Articles

Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with Multiple Myeloma Who Have Received 1 or More Prior Lines of Therapy

X. Steven Xu, Sam Liao, PhD, Meletios A Dimopoulos, Pieter Sonneveld, MD PhD, P. Joy Ho, Andrew Belch, MD, Merav Leiba, MD, Marcelo Capra, MD PhD, David Gomez, MD, Eva Medvedova, MD, Shinsuke Iida, MD PhD, Chang-Ki Min, MD, Ming Qi, Jordan Schecter, Nushmia Z. Khokhar, Xiaoyu Yan, Liping Zhang, Pamela L. Clemens

Blood (2016) 128 (22): 3340.

https://doi.org/10.1182/blood.V128.22.3340.3340

Published: 2016

Journal Articles

Pharmacogenetic Markers of Treatment Response of Imatinib Mesylate in Chronic Myeloid Leukemia Brazilian Patients

Natália M Vieira, Renata Leite, Fabíola Reginato, Marília Zandoná, Tito Vanelli Costa, Laura Fogliatto, MD, Rafael Linden, Marina Venzon Antunes, Arnaud Capron, Pierre Wallemacq, Sandrine Wagner, Vanessa Mattevi, Marcelo Capra, MD PhD

Blood (2016) 128 (22): 5458.

https://doi.org/10.1182/blood.V128.22.5458.5458

Published: 2016

Journal Articles

Warning As Defiened By European Leukemia Net 2013 (ELN 2013) In Chronic Phase Chronic Myeloid Leukemia (CP-CML) Corresponds To Warning In The Clinical Practice?

Blood (2013) 122 (21): 5176.

https://doi.org/10.1182/blood.V122.21.5176.5176

Published: 2013

Journal Articles

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy and Safety Of Siltuximab, An Anti-Interleukin-6 Monoclonal Antibody, In Patients With Multicentric Castleman’s Disease

Blood (2013) 122 (21): 505.

https://doi.org/10.1182/blood.V122.21.505.505

Published: 2013

Journal Articles

The Impact of Cytogenetic Response At 6 Months of Therapy in Global Survival of Patients with Chronic Myeloid Leukemia Treated with Imatinib in the South of Brazil

Laura Fogliatto, MD, Marcelo Capra, MD, Mariza Schaan, MD, Mario Sérgio Fernandes, MD, Tito Vanelli Costa, MD, Mayde Seadi Torriani, Katia Fassina, MD, Christina G S Fraga, MD, Mayla Baron, Dayane Koshiyama, Natássia Machado, Liane Esteves Daudt, MD, PhD, Lucia Silla, MD, PhD

Blood (2012) 120 (21): 4453.

https://doi.org/10.1182/blood.V120.21.4453.4453

Published: 2012

Journal Articles

The Role of Early Cytogenetic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib and the Impact of Adherence and Comorbidities

Blood (2011) 118 (21): 4423.

https://doi.org/10.1182/blood.V118.21.4423.4423

Published: 2011

NARROW

Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3

Pooled Safety Analysis from Phase I-III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib

Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Subgroup Analysis By Number of Prior Lines of Treatment

Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab

Nanatinostat (Nstat) and Valganciclovir (VGCV) in Relapsed/Refractory (R/R) Epstein-Barr Virus-Positive (EBV + ) Lymphomas: Final Results from the Phase 1b/2 VT3996-201 Study

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

Oral Nanatinostat (Nstat) and Valganciclovir (VGCV) in Patients with Recurrent Epstein-Barr Virus (EBV)-Positive Lymphomas: Initial Phase 2 Results

Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis

Brazilian Real-World Multiple Myeloma (MM) Electronic Platform Register Project

Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor

Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor

Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with Multiple Myeloma Who Have Received 1 or More Prior Lines of Therapy

Pharmacogenetic Markers of Treatment Response of Imatinib Mesylate in Chronic Myeloid Leukemia Brazilian Patients

Warning As Defiened By European Leukemia Net 2013 (ELN 2013) In Chronic Phase Chronic Myeloid Leukemia (CP-CML) Corresponds To Warning In The Clinical Practice?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy and Safety Of Siltuximab, An Anti-Interleukin-6 Monoclonal Antibody, In Patients With Multicentric Castleman’s Disease

The Impact of Cytogenetic Response At 6 Months of Therapy in Global Survival of Patients with Chronic Myeloid Leukemia Treated with Imatinib in the South of Brazil

The Role of Early Cytogenetic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib and the Impact of Adherence and Comorbidities

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only